Promoting safer diabetes treatments for older adults
Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes
This study is testing ways to help older adults with type 2 diabetes safely switch from sulfonylureas to better treatment options by encouraging conversations with their doctors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 220 (estimated) |
| Ages | 45 Years and up |
| Sex | All |
| Sponsor | University Hospitals Cleveland Medical Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT05933174 on ClinicalTrials.gov |
What this trial studies
This study aims to improve patient safety for older adults with type 2 diabetes who are currently prescribed sulfonylureas, a class of medications associated with adverse effects. The researchers will identify patients aged 45 and older taking sulfonylureas and empower them to discuss alternative treatments with their primary care providers. Additionally, primary care providers will receive education on contemporary diabetes treatment guidelines and the risks and benefits of various medication classes. The goal is to facilitate informed discussions and promote safer treatment options in ambulatory settings.
Who should consider this trial
Good fit: Ideal candidates are adults aged 45 and older with type 2 diabetes currently prescribed sulfonylureas.
Not a fit: Patients with type 1 diabetes or those unable to engage in discussions about their treatment options may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer diabetes management and reduced adverse effects for older patients.
How similar studies have performed: Other studies have shown success in promoting safer medication alternatives in diabetes care, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 45 years * Type 2 diabetes (diagnosed on or before 12/31/2021) * Current/active prescription for one or more SU medications * Established care (≥2 visits) with UH primary care provider (PCP) since 2021 Exclusion Criteria: * Type 1 diabetes * PCP provides a reason why patient participation is inappropriate (e.g., known cost barriers without any alternatives, prior discussion with patient about alternatives, etc.) * Patient unable or unwilling to have conversation with their PCP regarding SU * Unable to provide informed consent
Where this trial is running
Cleveland, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Ian Neeland, MD — University Hospital Cleveland Medical Center
- Study coordinator: Ian Neeland, MD
- Email: ian.neeland@uhhospitals.org
- Phone: 216-844-5965
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.